Streetbeat News

BVAXF

BioVaxys Technology Corp

Industry

Research and Development in Biotechnology

Open

0.04

Mkt cap

11M

Volume

65K

High

0.04

P/E Ratio

-2.11

52-wk high

0.08

Low

0.04

Div yield

N/A

52-wk low

0.03

BioVaxys Technology Corp. has secured a 48-kg supply of GMP-grade lipid for its DPX-based vaccines, facilitating the restart of clinical studies and new preclinical studies.

Portfolio Pulse from

December 17, 2024 | 12:15 pm

BioVaxys Technology Corp. has joined the US Government's BARDA Rapid Response Partnership Vehicle to accelerate vaccine development for pandemic influenza and other biological threats.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.